TRAIL is a cancer‐specific proapoptotic protein and the soluble recombinant form of the protein (rTRAIL) has been widely tested in the clinical trials;[256] however, the low bioavailability has hindered its clinical application.[257] Previous studies demonstrate that EV‐mediated delivery of TRAIL (EV‐T) in a membrane‐bound form could more efficiently induce cell apoptosis. This evidence concerns the gene TNFSF10 and cancer.